T/R ratio and the content of the active compound in each product [Power / Sample Size]

posted by CECIF – Colombia, 2017-10-11 20:18 (2251 d 20:50 ago) – Posting: # 17887
Views: 4,816

I have been following the tutorial in biostatistics by SA Julious (2004, DOI:10.1002/sim.1783). There, he mentions that it is possible to expect a priory a T/R ratio different to the unity (in a extent 0.8 to 1.20). However it is not clear to me, what criteria or in which cases can I assume an apriori ratio as big as 0.8 or 1.20, if knowingly I am trying to demonstrate bioequivalence and then I should be expecting a T/R ratio of 1.00.

In a particular case I happen to have a test product with content of the active compound that is above 110% of the content of the reference product. Could this product be evaluated for bioequivalence, by designing a study with an apriori T/R ratio of 1.10?

Edit: Category changed; I think this one fits better (was “Design Issues”). [Helmut]

Complete thread:

UA Flag
 Admin contact
22,824 posts in 4,786 threads, 1,632 registered users;
23 visitors (0 registered, 23 guests [including 2 identified bots]).
Forum time: 16:08 CET (Europe/Vienna)

In these matters the only certainty is
that nothing is certain.    Pliny the Elder

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz